David Budd, CEO of genedrive says adoption of point of care genetic testing in emergency settings will help save lives and money. However, innovators need to work to persuade healthcare funders to adopt these life-saving technologies.
Ahead of World Stroke Day, David Budd, CEO of genedrive plc, underscores the growing role of pharmacogenetics in personalised medicine and how its application can decrease the odds of secondary cerebrovascular disease.
Insights from David Budd, CEO of genedrive, on the advances in pharmacogenetic testing technology to maintain quality of care and treatment optimisation in acute medical settings.
